Read by QxMD icon Read


Josep Franch-Nadal, Javier Mediavilla-Bravo, Manuel Mata-Cases, Didac Mauricio, David Asensio, Jordi Sarroca
OBJECTIVE: To describe the prevalence of known and ignored type 2 diabetes mellitus (T2DM) among primary care physicians (PCP), as well as the treatment used and the degree of metabolic control reached. MATERIAL AND METHODS: Descriptive cross-sectional study on national level. The participants were randomly selected PCPs, members of the redGDPS Foundation. A total of 495 PCP were enrolled. Capillary HbA1c measurement was done with a A1CNow+(®) device and a diabetes-related survey specifically designed for the study was administered to the participants...
May 2017: Endocrinología, Diabetes y Nutrición
F Araújo, N Shrestha, M J Gomes, B Herranz-Blanco, D Liu, J J Hirvonen, P L Granja, H A Santos, B Sarmento
Oral delivery of proteins is still a challenge in the pharmaceutical field. Nanoparticles are among the most promising carrier systems for the oral delivery of proteins by increasing their oral bioavailability. However, most of the existent data regarding nanosystems for oral protein delivery is from in vitro studies, lacking in vivo experiments to evaluate the efficacy of these systems. Herein, a multifunctional composite system, tailored by droplet microfluidics, was used for dual delivery of glucagon like peptide-1 (GLP-1) and dipeptidyl peptidase-4 inhibitor (iDPP4) in vivo...
May 19, 2016: Nanoscale
Francesc Formiga, Ricardo Gómez-Huelgas, Leocadio Rodríguez Mañas
The prevalence of type 2 diabetes mellitus increases with age, reaching rates around 30% in those over 75 years. The type 2 diabetes mellitus in the elderly has different pathophysiological and clinical characteristics from those of the younger diabetic patient. Some differential aspects in this population are the lower life expectancy and the frequent comorbidity, frailty and associated disability. Avoiding hypoglycemia is a therapeutic priority, given their increased risk of severe hypoglycemia. It is a situation in which the benefits of intensive glycemic control are virtually non-existent, thus prevention of side effects of treatments becomes a priority...
January 2016: Revista Española de Geriatría y Gerontología
J M Amate, T Lopez-Cuadrado, N Almendro, C Bouza, Z Saz-Parkinson, R Rivas-Ruiz, J Gonzalez-Canudas
OBJECTIVE: Our review analyses the studies that have specifically compared the association iDPP4/metformin with glimepiride/metformin, both in second line pharmacotherapy of type 2 diabetes mellitus (DM2). METHODS: Systematic literature review with a meta-analysis of clinical trials comparing glimepiride with any iDPP4, both used together with metformin as a second line treatment of DM2. The effectiveness variables used were as follows: %HbA1c variation, fasting plasma glucose variation, patients achieving the therapeutic objective of HbA1c <7%, treatment dropouts due to lack of effectiveness and rescue treatments needed...
March 2015: International Journal of Clinical Practice
J Mancera-Romero, A Hormigo-Pozo, J Fernández-Arquero, A Baca-Osorio, M J Aparicio-Cervantes, L Muñoz-González
INTRODUCTION: The aim of the study is to describe the pattern of use of hypoglycemic agents in a primary health care district of Málaga between the years 2008-2012. MATERIAL AND METHOD: Cross-sectional descriptive study. Málaga health district. Population of 609,781 inhabitants; 42,060 people in the diabetes process. Therapeutic sub-group A10 (drugs used in diabetes). Data is presented as defined daily dose (DDD). Years 2008-2012. Measures of frequency. RESULTS: The population grew by 0...
January 2014: Semergen
Antoni Sicras-Mainar, Beatriu Font-Ramos, Cecilia Roldán-Suárez, Ruth Navarro-Artieda, Jordi Ibáñez-Nolla
OBJECTIVES: To determine compliance, metabolic control, complications and healthcare costs of patients treated with metformin started a second antidiabetic drug in patients with type 2 diabetes (T2DM). PATIENTS AND METHODS: Design multicenter observational retrospective. Patients were evaluated ≥30 years (age), treated with metformin and started a second antidiabetic treatment during 2008-2009. There were 4 patient groups (metformin and another antidiabetic): a) dipeptidyl peptidase-4 inhibitors (IDPP4), b) sulfonylureas, c) glitazones and d) insulin...
December 2013: Endocrinología y Nutrición: órgano de la Sociedad Española de Endocrinología y Nutrición
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"